"i believe they are working on a new catheter as we speak" that sounds expensive.. Have they the bandwidth for that type of approach? Do we have any public references where they have mentioned this?
So much of perceived value is in patents and protections for innovation.
Does anyone have execution risk factored into their models with the succession of the technology internally?? or from competitors?
Ann: Imricor Commences VISABL-AFL Trial for US FDA Approval, page-6
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
-0.015(2.61%) |
Mkt cap ! $151.2M | |||
| Open | High | Low | Value | Volume |
| 58.0¢ | 58.0¢ | 56.0¢ | $31.78K | 56.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 54.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.5¢ | 1711 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMR (ASX) Chart |